Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study – Endpoints News
Endpoints News |
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study
Endpoints News And the biotech now plans to boost the number of patients in a registration study so they can provide clear evidence of the gene therapy's ability to beat the current standard of care using factor replacement therapy. The company will boost enrollment … BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene … BioMarin Pharma (BMRN) Reports 2-Yr Clinical Data from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec … BioMarin's valoctocogene roxaparvovec shows long-term treatment effect in hemophilia A study |
